Last reviewed · How we verify
Oxaliplatin, capecitabine, radiotherapy
Oxaliplatin, capecitabine, radiotherapy is a Small molecule drug developed by Sanofi. It is currently in Phase 2 development.
At a glance
| Generic name | Oxaliplatin, capecitabine, radiotherapy |
|---|---|
| Sponsor | Sanofi |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) (PHASE2)
- SCRT-CAPEOX-Serplulimab for MSS/pMMR Rectal Cancer With Oligometastases (PHASE2)
- Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body (PHASE3)
- MRI-Guided Adaptive Radiation Therapy for Organ Preservation in Rectal Cancer (PHASE1)
- SCRT-NALIRIXELOX+Sintilimab as TNT for High-Risk LARC (NA)
- Neoadjuvant FOLFOXIRI and Chemoradiotherapy Versus Neoadjuvant CAPOX/FOLFOX and Chemoradiotherapy Followed by Surgery or a Watch-and-Wait Approach in High Risk Locally Advanced Rectal Cancer (PHASE3)
- Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer (PHASE2)
- Neoadjuvant Chemotherapy and PD-1 Inhibitor for Locally Advanced Rectal Cancer（CONTROL-01） (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Oxaliplatin, capecitabine, radiotherapy CI brief — competitive landscape report
- Oxaliplatin, capecitabine, radiotherapy updates RSS · CI watch RSS
- Sanofi portfolio CI
Frequently asked questions about Oxaliplatin, capecitabine, radiotherapy
What is Oxaliplatin, capecitabine, radiotherapy?
Oxaliplatin, capecitabine, radiotherapy is a Small molecule drug developed by Sanofi.
Who makes Oxaliplatin, capecitabine, radiotherapy?
Oxaliplatin, capecitabine, radiotherapy is developed by Sanofi (see full Sanofi pipeline at /company/sanofi).
What development phase is Oxaliplatin, capecitabine, radiotherapy in?
Oxaliplatin, capecitabine, radiotherapy is in Phase 2.